Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

121. New Company Created to Develop Novel Technology to Treat Diabetes

New Company Created to Develop Novel Technology to Treat Diabetes 18/05/2016The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, today announce the creation of Islexa, a new company developing a novel technology to produce laboratory grown islets, the organoids responsible for insulin production. The technology could bring the option of an islet transplant to thousands more patients with type I diabetes. Currently in the UK, only 30-50 patients with hypoglycaemic un


122. BTG plc Announces Final Results

BTG plc Announces Final Results 17/05/2016London, UK – BTG plc, the specialist healthcare company, today announces its final results for the yearFinancial summaryGroup revenue grew 22% to £447.5m (2014/15: £367.8m); underlying revenue growth at constant currency was 14%Operating profit before acquisition adjustments and reorganisation costs rose to £93.0m (2014/15: £67.9m)Profit before tax of £57.5m (2014/15: £26.7m) reflects underlying growth and cost di


123. Isansys Wireless Monitoring Platform Transforming Patient Care Around

Isansys Wireless Monitoring Platform Transforming Patient Care Around the World 01/06/2016Abingdon, UK – Isansys Lifecare, a new generation digital healthcare company, and the market-leader in real-time patient data capture and analysis systems, sees rapidly increasing global demand for its Patient Status Engine wireless patient monitoring platform, as it ships more systems to hospitals in India, Germany, Scotland and Norway. The company’s 2nd generation


124. Oxford BioMedica and Green Cross LabCell Form a Partnership to Develop

Oxford BioMedica and Green Cross LabCell Form a Partnership to Develop Gene-modified NK Cell Therapeutics in Cancer 02/06/2016Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline of differentiated products in cancerOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces that it has entered into a Res


125.  Melissa Gardiner Joins Consilium Strategic Communications from AstraZ

 Melissa Gardiner Joins Consilium Strategic Communications from AstraZeneca06/06/2016Consilium Strategic Communications, a global leader in strategic healthcare communications, today welcomes Melissa Gardiner from AstraZeneca's global media relations team.Melissa joins Consilium as an Executive Consultant having gained four years' broad experience in global media relations, social media and digital communications at the FTSE 100 pharmaceuticals leader, AstraZeneca.Mary-Jane Elliott, Managin



Page 25 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019